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Abstract 
To study the structural basis of pathological remodelling and altered calcium channel functional states in the heart, we sought to 
re-purpose high-affinity ligands of the cardiac calcium channel, th  ryanodine receptor (RyR2), into super-resolution imag ng 
probes. Imperacalcin (IpCa), a scorpion toxin peptide which induces channel sub-conduction states, and DPc10, a synthetic peptide 
corresponding to a sequence of the RyR2, which replicates arrhythmogenic CPVT functional changes, were used in fluorescent 
imaging experiments.  
Isolated adult rat ventricular cardiomyocytes were saponin-permeabilised and incubated with each peptide. IpCa-A546 became 
sequestered into the mitochondria. This was prevented by treatment of the permeabilised cells with the ionophore FCCP, revealing 
a striated staining pattern in confocal imaging which had weak colocalisation with RyR2 clusters. Poor specificity (as an RyR2 
imaging probe) was confirmed at higher resolution with expansion microscopy (proExM) (~70 nm). 
DPc10-FITC labelled a striated pattern, which had moderate colocalisation with RyR2 cluster labelling in confocal and proExM. 
There was also widespread non-target labelling of the Z-discs, intercalated discs, and nuclei, which was unaffected by incubation 
times or 10 mM caffeine. The inactive peptide mut-DPc10-FITC (which causes no functional effects) displayed a similar labelling 
pattern. 
Significant labelling of structures unrelated to RyR2 by both peptide conjugates makes their use as highly specific imaging probes 
of RyR2 in living isolated cardiomyocytes highly challenging. 
We investigated the native DPc10 sequence within the RyR2 structure to understand the domain interactions and proposed 
mechanism of peptide binding. The native DPc10 sequence does not directly interact with another domain, and but is downstream 
of one such domain interface. The rabbit Arg2475 (equivalent to human Arg2474, mutated in CPVT) in the native sequence is the 
most accessible portion and most likely location for peptide d sturbance, suggesting FITC placement does not impact peptide 
binding.  
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Introduction 
The ryanodine receptor (RyR), the largest known ion channel, is central 
to the process of excitation-contraction (EC) coupling 1, and has been the 
focus of extensive research over the last few decades. RyRs are 
responsible for Ca2+ release from the sarcoplasmic reticulum (SR) 2, 
which occurs when intracellular [Ca2+]i reaches a threshold 
concentration, in a process termed Ca2+-induced Ca2+ release (CICR) 3. 
A single homo-tetrameric, mushroom-shaped RyR consists of a 
cytoplasmic region which interacts with a plethora of ligands, and a 
transmembrane region containing the ion-conducting pore 4.  
Advancements in microscopy have progressed the understanding that 
RyRs self-assemble into clusters, forming discrete functional calcium 
release units (also known as nanodomains). Electron microscopy gave 
the first glimpses of the profile of individual RyRs in peripheral 
couplings (interface with sarcolemmal surfaces), and in dyads (interface 
with t-tubule membranes) 5–7. More recently, electron tomography 
offered more detailed 3D information of cluster geometry 8,9.  
Super-resolution techniques, which surpass the diffraction limit of light 
and use fluorescent markers to label targets, have revealed more insights 
into cluster geometry and the proteins present within these nanodomains. 
RyR2 clusters as imaged by confocal microscopy (limited to ~200 nm 
resolution) appear as smooth punctate structures, leading to over-
estimations of cluster size in terms of RyRs per cluster; whereas 
dSTORM, which increases the resolution to ~20nm, revealed 
significantly smaller cluster sizes 10–12. The molecular-level description 
of peripheral nanodomains was obtained using the sub-10 nm resolution 
technique DNA-PAINT, sufficient to localise individual RyRs 13. More 
recently, the prevalence of RyR2 phosphorylation at the individual 
channel level has been studied with X10 expansion microscopy (ExM) 
14. 
The efficacy of super-resolution imaging research depends on highly 
specific fluorescent probes, which possess high specificity for the target. 
Various molecules have been used as probes, such as antibodies, 
nanobodies, smaller protein-binding scaffolds, and peptide ligands 15–18. 
We hypothesised that two peptides with high binding specificity for the 
RyR, the scorpion toxin imperacalcin (IpCa) 19 and the synthetic DPc10 
20, might be effective super-resolution imaging probes, and moreover 
might permit the visualisation of RyRs in different functional st tes (open 
channel, IpCa; CPVT-like substate, DPc10). Reliable and highly specific 
non-antibody probes for this protein would also enable multiplexing, by 
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labelling other combinations of protein targets with antibodies at the 
same time. Furthermore, these fluorescent probes would allow 
understanding of possible cluster rearrangements incurred by the 
functional effect of each peptide.  
IpCa is a 3.7 kDa peptide found in the venom of the Pandinus imperator 
scorpion 19,21. IpCa binds to the RyR2 with high affinity (Kd = 5-10 nM) 
and induces long-lasting sub-conductance states 22,23. The 33 amino acid 
peptide has an overall net charge of +8 (at physiological pH), which is 
clustered on one side, forming a dipole moment (Supplementary Figure 
1A) 23,24. The exact binding site on RyR2 is unconfirmed, one study 
suggests IpCa enters the channel’s vestibule pore and binds an internal 
site 25, whereas a study using IpCa-biotin-streptavidin reported to bind to 
the cytoplasmic moiety, far from the trans-membrane pore 
(Supplementary Figure 1B) 26. Whether the peptide causes its effects by 
steric hindrance or an allosteric mechanism is unconfirmed 23,27,28. 
Previous imaging with a fluorescent IpCa conjugate in saponin-
permeabilised cardiomyocytes confirmed an intracellular localisation in 
the sarcoplasm 24, but lacked confirmation of positive RyR2 labelling 
with a dual stain.   
The synthetic peptide DPc10 corresponds to the RyR2 amino acid 
sequence Gly2460-Pro2495 (full sequence provided in methods) 20, and 
is thought to compete with the native sequence, disturbing the domain 
interaction. DPc10 destabilises the channel, in a way that mimics the 
human CPVT mutant RyR2 bearing R2474S, enhancing ryanodine 
binding, causing hyper-sensitisation 20, increasing SR Ca2+ leak 29, 
reducing CaM binding 30, without causing FKBP dissociation 31,32. A 
mutant peptide (mut-DPc10) bearing the equivalent CPVT mutation does 
not affect channel function 20, suggesting the sequence is critical for 
functional impact. The effect of the peptide is linked with a ypothesis 
made in a different peptide probe study with the peptide DP4 33, which 
regards inter-domain interactions as being important for regulating 
channel function and stabilisation. This was partly informed by 
observations of clustered mutations in 2 domains, the N-terminal domain 
(1-600) and central domain (2000-2500). The native DPc10, residing in 
the central domain, is thought to have a partner binding region within the 
N-terminal domain 34. The DPc10 peptide disturbs this domain 
interaction, unzipping in order to elicit the functional effects 20. Previous 
studies using fluorescent DPc10 as an imaging probe revealed a striated 
labelling pattern in isolated cardiomyocytes, but lacked confirmation of 
RyR2 specificity with a dual-label 35,36.  
To evaluate whether the peptides could effectively label RyR2 in situ, we 
used fluorescent conjugate forms IpCa-Alexa Fluor 546 (IpCa-A546) and 
DPc10-fluorescein (DPc10-FITC) to label living isolated rat ventricular 
cardiomyocytes, and evaluate specificity and colocalisation with 
confocal microscopy and protein retention ExM (proExM) 37. Our 
findings suggest that using both peptides as highly specific imaging 
probes for RyR2 in isolated rat cardiomyocytes is highly c allenging, 
given poor colocalisation with RyR2 antibody labelling, and prevalence 
of substantial labelling of other structures in the cardiomyocyte. We also 
looked at high-resolution atomic models of RyR2 structure to understand 
the native DPc10 sequence and domain interactions, and the implications 
of FITC placement on peptide binding. The native sequence is within a 
well-structured region (helical domain 1 (HD1)). The native sequence 
itself is not directly interacting with an N-terminal domain, but is 
downstream of such a domain interface involving HD1. The native 
sequence is largely enclosed by neighbouring residues and inaccessible 
to an exogenous peptide. The rabbit Arg2475 residue (equivalent to the
human Arg2474) is the most accessible part of the sequence.  
Results 
IpCa-A546 imaging  
We sought to evaluate whether a fluorescent conjugate of IpCa could 
effectively label RyR2 in situ in isolated rat ventricular c diomyocytes. 
We conjugated IpCa to Alexa Fluor 546 (Figure 1A), a fluorophore which 
would be compatible with the super-resolution technique proExM. The 
biological activity of this conjugate, in terms of retained high affinity for 
RyR2, was verified akin to that previously shown 24. 
Following isolation, cardiomyocytes were saponin-permeabilised to 
allow delivery of the peptide probe. Once attached to laminin-coated 
chambers, cardiomyocytes were incubated with 5 µM IpCa-A546 in a 
mock intracellular solution (with 10 mM caffeine and low free [Ca2+]) 
for 30 minutes at room temperature. Initially, IpCa-A546 was 
sequestered into the mitochondria, revealing a labelling pattern in 
confocal imaging after fixation that resembled the mitochondrial 
importer tom20 (Figure 1B). The reason for this sequestration is likely 
due to the net positive charge on the IpCa peptide 23,24. In order to prevent 
mitochondrial sequestration, permeabilised cardiomyocytes were 
incubated with the ionophore FCCP (30 µM, 10 mins) prior to peptide 
incubation. FCCP allows H+ ions through membranes, effectively 
eliminating the membrane potential of the mitochondria 38, which we 
hypothesised was the driving force for positively charged peptide 
accumulation in the mitochondria. By pre-treating permeabilised 
cardiomyocytes with FCCP, IpCa-A546 labelled in a striated pattern on 
top of an underlying background staining pattern throughout the cell 
(Figure 1C), which resembles the original mitochondrial labelling. 
Additionally, there was nuclear labelling (not shown).  
To determine whether the striated pattern was due to RyR2 labelling, we 
immunolabelled the cells using RyR2 antibodies. After immunolabel ing, 
it was evident even at ~ 250 nm resolution obtained with confo al 
microscopy that whilst the IpCa-A546 staining was at a similar location 
in the sarcomere, it stained a continuous structure visually similar to the 
Z-discs 39, unlike the punctate nature of RyR2 clusters (Figure 1C).  
Line-profile plots transversely (along a single Z-disc) and longitudinally 
(perpendicular to the Z-discs) show the peptide labelling possesse  
similar Z-disc periodicity but different characteristic (Figure 1D). For 
instance, transversely (left), IpCa-A546 is mostly uniform, while RyR2 
is variable with prominent increases in intensity at locatins of clusters. 
Longitudinally (right), while RyR2 labelling rises and falls with clear 
gaps between each Z-dizc, IpCa-A546 has a Z-disc periodicity, but is 
much less prominent due to high (and even) cytoplasmic background in 
between Z-discs. These observations further suggest that IpC-A546 
striated labelling might reflect that of the Z-disc. 
The degree of colocalisation between IpCa-A546 and RyR2 was assessed 
by thresholding 2-color confocal images and using the coloc2 Fiji plugin. 
Colocalisation was assessed in terms of correlation (Pearsons coefficient 
ranging from -1 to 1, whereby 1 is perfect correlation, 0 is no correlation, 
and -1 is perfect anti-correlation), and in terms of co-existence, also 
known as fractional overlap (Manders coefficient, ranging betwe n 0 and 
1, whereby 1 is perfect overlap, 0 is no overlap) 40. The Costes statistical 
approach states whether the result was due to chance 41, determining what 
percentage of randomised images have worse correlation than the real 
image. If greater than 95% (>0.95) of randomised have worse c r lation, 
then the result is not due to chance. For instance, 1.0 or 00% means none 
of the randomised images had better correlation, 0.5 means 50% had 
better correlation, and given it is <0.95 the result could be due to chance. 
IpCa-A546 exhibited weak colocalisation with RyR2 in confocal data, 
with weak anti-correlated Pearsons coefficient -0.05 ± 0.2 suggesting the 
two patterns have no correlation. The fractional overlap Manders 
coefficient 0.08 ± 0.12 (proportion above the auto-threshold of RyR2) 
suggests there was almost no co-occurrence. Manders may be a less
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appropriate parameter given one structure (RyR2) dominates in terms of 
area, due to high background levels in IpCa-A546 images leading to 
higher thresholds and thus selecting fewer pixels. The Costes value 0.27 
(<0.95) indicates these figures could be due to random chance, likely 
attributable to the high background/noise of IpCa images. 
We used proExM to verify the degree of colocalisation at higher 
resolution. As suggested by confocal colocalisation analysis, mo t of the 
IpCa-A546 labelling was outside of regions of RyR2-positive labelling 
(Figure 1E). IpCa-A546 appeared to label the Z-discs (the continuous 
borders of the sarcomere), and the background traces of mitochondrial 
sequestration were prominent.  
Thus, in our hands, IpCa-546 does not fill the criteria of a highly specific 
imaging probe of the RyR2 in living isolated cardiomyocytes. We also 
used a different fluorophore conjugate of the IpCa, with Janelia Fluor 
549, but this was also heavily sequestered into mitochondria, and after 
FCCP showed little RyR2 colocalisation (not shown). With the present 
methods, IpCa appears to be ineffective as an imaging probe deliv red in 
living cardiomyocytes, attributable largely to the significant positive 
charge leading to significant background binding of numerous structures 
in addition to the target protein RyR2. 
Figure 1 – Imperacalcin-A546 as an RyR2 imaging probe in isolated rat ventricular cardiomyocytes. (A) Schematic of IpCa-A546 conjugate. 
(B) Isolated ventricular cardiomyocytes were incubated with 5 µM IpCa-A546 for 30 minutes. Mitochondrial sequestration was visible in co focal 
images (B-i), resembling the pattern typical of the mitochondrial p otein tom20 (B-ii). (C) After treatment with the ionophore FCCP (30 µM for 10 
minutes), IpCa-A546 uniform striated labelling was visible (green), behind the background trace of residual mitochondrial sequestration. IpCa-A546 
shared a weak overlap with RyR2 labelling pattern (magenta). (D) Line profiles plots (red lines in C) revealed differences in the two labelling patterns. 
IpCa-A546 labelling was uniform along a single sarcomere while RyR2 varied, and across multiple sarcomeres the Z-disc peaks were less prominent 
in IpCa-A546 plots due to high background between Z-discs. (E) Expansion microscopy demonstrates the prevalence of non-target labelling of Z-discs, 
and weak colocalisation with RyR2 clusters. Scale bars, 2 µm (B,C), 8 µm (E). 
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DPc10-FITC imaging 
We next explored DPc10 as an imaging probe for RyR2. A fluorescent 
conjugate of DPc10 with an N-terminal 5’ carboxyfluorescein (FITC) 
moiety was synthesised (Figure 2A). The predicted peptide fol ing (using 
JPred software) into 2 alpha helices is like the folding of the native RyR2 
sequence, as displayed for the schematic of the conjugate in Figure 2A. 
The FITC on the N-terminus is proposed to not inhibit peptide binding to 
the RyR2, given it is placed far from the Arg residue which is thought to 
be critical for binding, and in a solvent facing space 20. Placement of FITC 
at this site has previously been shown to preserve the peptide’s ability to 
bind and incur the increase to spark frequency and decrease to SR load 
35.  
We incubated saponin-permeabilised isolated cardiomyocytes with 5 µM 
DPc10-FITC in a mock intracellular (low free [Ca2+]) solution, for 30 
minutes at room temperature. After immunolabelling with antibodies for 
RyR2, confocal images showed that DPc10-FITC labelled in a striated 
pattern, which displayed moderate colocalisation with RyR2 clusters 
(Figure 2B). The DPc10-FITC pattern was qualitatively more punctate 
than IpCa-A546 (referring to the roundness of the blobs, a characteristic 
of RyR2 labelling). Despite the instances of colocalisation at each Z-disc, 
there was also a significant amount of non-RyR2 labelling of intercalated 
discs, nuclei, and M-lines.  
Line-profile plots show peptide labelling was like RyR2 but was not 
identical (Figure 2C). For instance, transversely (along a single Z-disc) 
(left) RyR2 staining and DPc10-FITC showed similar periodicity in stain 
intensity (left arrow), but also instances where an increase in RyR2 
intensity lacked a respective DPc10 increase (right arrow). 
Longitudinally (perpendicular to the Z-discs) (right), the DPc10-FITC 
M-line labelling is apparent as smaller peaks in between those of the Z-
discs. 
The colocalisation of DPc10-FITC with RyR2 was assessed, as 
performed previously for IpCa-A546. DPc10-FITC exhibited moderate 
colocalisation with RyR2 in confocal data, with a fractional overlap 
Figure 2 – DPc10-FITC as an RyR2 imaging probe in isolated rat ventricular cardiomyocytes. (A) Schematic of DPc10-FITC conjugate, using 
the RyR2 structure of the native DPc10. FITC was placed t the N-terminus, far from the Arg residue critical for binding. (B) Isolated ventricular 
cardiomyocytes were incubated with 5 µM DPc10-FITC (cyan) for 30 minutes. The striated labelling pattern overlapped with RyR2 (red). Non-target 
labelling of nuclei (N), intercalated discs (ID) and M-lines (M) was visible in DPc10-FITC. (C) Line profiles plots (red lines in B) revealed differences 
in the two labelling patterns. Some line profile intensity changes were common between DPc10-FITC and RyR2 labelling along  si le sarcomere 
(left arrow), although other RyR2 peaks did not appear in DPc10-FITC (right arrow). Across multiple sarcomeres the M-line abelling of DPc10-FITC 
is apparent. (D) Expansion microscopy suggests some positive labelling of DPc10-FITC at RyR2 clusters (arrows), as well as non-target labelling of 
Z-discs. Scale bars, 8 µm (B,D), 1 µm (B-inset), 2 µm (D-inset). 
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Manders coefficient 0.54 ± 0.08 (proportion above the auto-threshold of 
RyR). The labels were moderately positively correlated (Pearsons 0.45 ± 
0.07), and the Costes value 1 indicates these findings are real and not due 
to random chance (>0.95). 
Despite FITC losing a significant amount of fluorescence i  the proExM 
protocol (and thus the resolution is poor for that channel), increased 
RyR2 image resolution would help assess colocalisation. proExM 
revealed that DPc10-FITC labelling was present at some RyR2 clusters 
(arrows showing white pixels in composite image), but also in larger 
amounts outside of RyR2 clusters, labelling Z-discs (Figure 2D).  
Altogether, these results suggest that DPc10-FITC does succesfully 
label a fraction of RyR2, but there was also a proportion of on-target 
labelling at sites that were not RyR2 clusters, including Z-discs, M-line, 
nuclei and intercalated discs.  
Alterations to improve DPc10-FITC labelling and understand non-
target labelling 
To explore the conditions which promote DPc10-FITC binding to RyR2, 
we incubated isolated cardiomyocytes with the peptide for a longer 
period of up to 60 minutes (Figure 3A). The longer incubation did not 
qualitatively affect the uniform striated labelling, and the non-target 
labelling remained.  
We also incubated cardiomyocytes with the peptide in the presence of 10 
mM caffeine (Figure 3B), which activates the channel and increases open 
probability 42,43, as has been shown to enhance access of the peptide 
previously 35. Caffeine did not qualitatively change the amount of 
punctate labelling, and the non-target labelling was unchanged. Whilst 
these results do not offer a conclusive, quantitative description of the 
change of % colocalisation between RyR2 and DPc10, they confirm that 
even with conditions optimised for RyR2 activation, there remained a 
significant amount of non-target labelling, which prevents DPc10-FITC 
being used as a specific imaging probe of RyR2 in living isolated 
cardiomyocytes. 
To get a perspective on non-target binding, we used a similar peptide 
mut-DPc10, which bears the mutation equivalent to the R2475S found in 
CPVT, and has been shown to cause no functional defects to the RyR2 
channel. The inactive peptide fails to mediate labelling of RyR2 34, 
suggesting it loses its ability to bind RyR2.  Using mut-DPc10-FITC we 
sought to learn whether the similar peptide-fluorophore conjugate also 
had non-target labelling. In confocal imaging, 5 µM mut-DPc10-FITC 
was like DPc10-FITC, it labelled in a striated pattern, but also had a 
significant amount of non-target labelling of Z-discs, nuclei and 
intercalated discs. (Figure 3C). This suggested that staining by these 
peptides does not correlate with functional data, wherein the peptides are 
substantially different. We explored whether the FITC fluorophore, 
common to both peptides, itself might influence the localisation of the 
peptide conjugate and account for non-target labelling. When deliver d 
by itself, 5 µM FITC labelled an altogether different pattern, appearing 
to be sequestered in vesicles (Figure 3D). This suggests that the FITC 
fluorophore was not driving the localisation of the conjugate for 
subsequent staining patterns.  
RyR2 structural analysis of DPc10 native sequence, peptide binding site 
and domain interactions 
Finally, we examined the native DPc10 sequence within various cryo-
EM RyR2 structural models, PDB codes of which are detailed in the 
methods. We investigated whether there was a direct interaction by the 
native DPc10 sequence with an N-terminal domain, as suggested in the 
unzipping hypothesis 20 and alluded to by reports of peptide directly 
binding the N-terminal domain 34. We aimed to shed light on the 
mechanism of peptide binding and disturbing the domain interface, and 
to determine the implication of FITC placement on peptide binding. 
Regarding the location and structure of the native DPc10 sequence (RyR2 
sequence 2460-2495), it was previously described as locating in a centr l 
domain, but in modern descriptions the nomenclature has changed, and 
the RyR2 ‘central domain’ refers to the domain with sequence 3636-4020 
44,45. Therefore, DPc10 exists within helical domain region 1 (HD1), 
residues 2110-2679, not the ‘central domain’.  
To investigate DPc10 domain interaction with the N-terminal domain and 
the idea that the peptide binds to the N-terminal domain directly, we 
looked to see whether the region containing the DPc10 sequence 
interacted with an N-terminal domain. The N-terminal domain of the 
Figure 3 – Alterations to improve DPc10-FITC target binding and understand non-target labelling. (A) Increasing the peptide incubation time 
to 60 minutes did not affect non-target labelling. (B) No improvement in non-target labelling was seen when including 10 mM caffeine in the peptide 
incubation to increase the odds of RyR2 activation. (C) 5 µM Mut-DPc10-FITC (which causes no functional alterations in RyR) produced an almost 
identical non-target labelling pattern. (D) 5 µM FITC (the fluorophore common to both DPc10 and mut-DPc10 conjugates) possessed an entirely 
different non-target labelling pattern when applied by itself, uggesting the fluorophore was not driving conjugate localisation. Scale bars, 8 µm (A-E). 
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neighbour subunit is in close proximity to HD1, but does not directly 
interact with the native DPc10 (~20 Å away) (Figure 4A). This N-
terminal domain interacts with other residues within HD1, notably 
Arg2419 and Ser2426. This interaction between the N-terminal domain 
and HD1 is upstream of DPc10 (Figure 4B), and of the residue Arg2475 
(equivalent to human Arg2474) which is mutated in CPVT. Another 
domain zip was observed in close proximity, involving this N-terminal 
domain and residues of the central domain, notably 3891-3894. We 
observed no intra-subunit (within the same monomer) domain interaction 
between the N-terminal domain and HD1 (Figure 4A). 
The simplicity of previous schematics of DPc10 peptide effect (based on 
direct interaction of native sequence with N-terminal domain) may be 
inappropriate, and we propose it may be updated to reflect that DPc10 
peptide may induce domain unzipping upstream of the exact binding site, 
without directly binding to the N-terminal domain, instead interfering 
with the native sequence interactions, allosterically disturbing upstream 
domain zips (Figure 4D). 
To gauge the likelihood and mechanism of peptide binding at the native 
sequence, we explored the structure and accessibility of this region. The 
DPc10 sequence within HD1 is largely inaccessible, surrounded by 
neighbouring helices, making most of the native sequence interactions 
internal surfaces, which were not exposed allowing disturbance by a 
peptide (Figure 4C). This well-structured region has a number of 
stabilising interactions which suggests that the degree of mobility is 
limited. Furthermore, this region does not become more accessibl  in the 
open confirmation, compared to the closed (Supplementary Figure 2B). 
Figure 4 – RyR2 structural analysis of the DPc10 native sequence, peptide binding site and domain interactions. (A) DPc10 native sequence 
exists in HD1, which comes into proximity with the neighbour subunit N-terminal domain. (B) This neighbour N-terminal domain does not interac  
directly with DPc10, but does interact with other residues within HD1 upstream of DPc10 and Arg2475 (in rabbit, equivalent to human Arg2474). 
There is also an interaction of the N-terminal domain with the central domain, in proximity to DPc10. (C) Most of the DPc10 sequence is internal and 
not exposed surfaces, surrounded by neighbouring helices of HD1. Arg2475 sits at the most exposed portion of the sequence. (D-i) Old schematic 
where peptide unzipping is by DPc10 sequence directly binding NTD. (D-ii) A proposed new schematic for the DPc10 domain zip interac ion, indicating 
that the native DPc10 sequence, within HD1, does not directly bind to N-terminal domain, but upstream residues of HD1 do. The central domain (C) 
zip is also in proximity. DPc10 peptide could interact with the native sequence Arg2475, disturbing the upstream interaction of HD1 with N-terminal 
domain.  
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However, the native residue Arg2475 sits at the most exposed part of the 
native sequence and interacts with several residues within HD1, and is 
thus the most accessible to be disturbed by a peptide. The native Arg2475 
interactions with other residues also seem to be unchanged between he 
open and closed conformations (Supplementary Figure 2B).  
Previously, it has been shown that DPc10 peptide binding is dependent 
on the peptide Arg residue 20. A similar peptide DP4 (RyR2 sequence 
2442-2477) shares one loop of the DPc10 structure, including this Arg 
(Supplementary Figure 2A), and similarly functionally depends on this 
residue 33, further supporting the idea that this peptide residue is crit cal 
for binding the RyR2.  
To summarise on the mechanism of peptide binding near the native 
sequence, whilst we have no direct evidence of the site of DPc10 peptid  
binding, our analysis of the structure of RyR2 in the locatin of DPc10 
sequence does not offer support to the suggestion that the peptide entirely
displaces the RyR2 sequence to corrupt a domain-domain interface. We 
suggest he peptide may bind at the exposed DPc10 Arg2475 residue, and 
this is dependent on its own Arg residue. Given this concept of eptide 
binding, we assume that the observations made with the DPc10-FITC 
were not likely to have been affected by fluorophore placement at the 
peptide N-terminus, given this was far from the Arg residue, and would 
be located in solvent exposed position. 
Interestingly, the DPc10 peptide binding site reported by FRET 
experiments is different from the location of the native DPc10 sequence 
within HD1, instead reporting to be around the handle region 35 
(Supplementary Figure 2C, left). The identify the site based on a set 
distance 56 Å away from FKBP and CaM. In the RyR2 structu e, the 
native sequence site is 100 Å from the location of the FKBP FRET 
partner (Supplementary Figure 2C, right), suggesting that this is not the 
site of binding they discovered, but they refer to the possibility that 
DPc10 may bind to the RyR2 in multiple sites.  
Altogether, this information raises questions over the exact loca ion and 
nature of DPc10 binding, either directly to an N-terminal domain, near 
the native sequence, or near the reported site based on FRET.  
Discussion 
Both IpCa-A546 and DPc10-FITC possessed a significant amount of 
non-target labelling at sites other than the RyR2. While there were 
instances of positive RyR2 labelling, the prevalence of negative labelling 
hampers their use as high specificity super-resolution imaging probes for 
the RyR2 when applied to living isolated cardiomyocytes.  
Despite failure to confirm specificity of the peptides for RyR2 in 
fluorescent imaging experiments, it is not disputed that bothpeptides 
IpCa and DPc10 bind to the RyR2. There is a wide body of evidence of 
the functional effects of both peptides in the literature 
20,22,24,25,29,31,34,36,46,47. 
Evidence of positive RyR2 labelling 
IpCa-A546 showed weak colocalisation with RyR2 in confocal imaging, 
and proExM revealed that the majority of IpCa-A546 was outside RyR2 
clusters, tending to uniformly label the Z-discs which are in the same 
rough plane as the clusters. The colocalisation seen at confocal level was 
likely due to poor resolution failing to discern the close (but not identical) 
localisations of these two probes, attributable in part to high background 
of IpCa-A546 traces within the mitochondria. The pattern of IpCa-A546 
near RyR2 clusters was neither punctate nor noticeably like the RyR2 
pattern, instead having a uniform pattern like g-actinin of the Z-disc. 
Binding of IpCa, which is thought to bind the channel’s open 
conformation 23, should be encouraged when the channels activate 
regularly and often, as was achieved with caffeine 42,43.
DPc10-FITC labelling on the other hand was more punctate (a 
characteristic pattern of RyR2 clusters) and showed moderate 
colocalisation with RyR2 in confocal imaging. proExM confirmed that 
DPc10-FITC did successfully label some RyR2 clusters, despite a 
significant amount of non-target labelling of the Z-disc. Coincidence at 
the super-resolution level was visible, but formal quantitation was not 
possible due to poor resolution in the FITC channel. Future exp riments 
with a proExM-compatible probe would be required to assess th  degree 
of target-specific binding at the nanometer scale. Caffeine treatment did 
not noticeably change the uniform Z-disc-like labelling pattern, 
confirming that even in conditions optimized for RyR2 specificity, non-
target labelling exists. It is of interest to quantify thechange in RyR2 
specificity by caffeine treatment in the future with a proExM-compatible 
conjugate, to determine whether the probe can reflect changes i  RyR2 
activation state. 
DPc10 binding conditions are difficult to speculate on given th  DPc10 
binding site is not confirmed. Previously DPc10-FITC access was 
enhanced by increased RyR2 activation and pre-bound non-fluorescent 
DPc10, although this confocal analysis demonstrated striated l belling 
which was not verified as specific RyR2 labelling 35.  
Given DPc10 effects do not easily reverse without long washout periods 
29,35, peptide dissociation is unlikely to account for the amount bound to 
RyR2. The inclusion of caffeine should ensure the channels remain 
activated so peptides can re-bind even if they dissociated.  
Use of a proExM-compatible mut-DPc10 conjugate, for colocalisation 
analysis in comparison to the active peptide, is desirable to xplore 
whether the peptide labelling patterns correlate with functio al binding 
data. 
Non-target labelling 
It might be possible to use IpCa and DPc10 as imaging probes if the 
challenges of non-target labelling are circumvented. Typical 
immunolabelling experiments with IgG primary antibodies circumvent 
non-target labelling in fixed cells by performing a blocking step o 
eliminate sites which randomly bind epitopes.  It remains to be seen 
whether it is possible to perform blocking to prevent sticking to these 
widespread structures, especially as blocking in the living cell is not 
possible without altering physiology and/or structure.  
The positive charge of IpCa lead to significant non-target labelling due 
to mitochondrial sequestration. The distribution of positive charges on 
the peptide are critical for binding to RyR1 23,25,48, so one would speculate 
that removing the charge to prevent this sequestration would also prevent 
the binding to the target RyR2.  
While significant non-target labelling of IpCa-A546 and DPc10-FITC 
renders them ineffective as super-resolution RyR2 imaging probes in 
isolated cardiomyocytes, they might still prove useful in SR lipid 
bilayers, or cell types lacking dense contractile machinery or prevalent 
membrane networks, for instance atrial cardiomyocytes, or HL-1 (atrial 
tumour) cell line. 
Previous exploits with fluorescent IpCa showed an intracellular 
localisation 24, and imaging with DPc10-FITC  inferred successful RyR2 
labelling by the striated labelling pattern 35. These results demonstrate the 
need to validate probe target specificity at higher resolution, and 
alongside an independent marker for the target of interest.  
DPc10 native sequence, peptide binding site and unzipping hypothesis 
We expected to find the native DPc10 sequence directly adjacent to and 
interacting with an N-terminal domain, as suggested by the domain zip 
hypothesis 33. We found that the native sequence was not itself interacting 
with an N-terminal domain, but that a region upstream of DPc10 did 
interact. It is possible that this is the inter-domain zip that is important for 
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regulating channel gating, and which is compromised in the CPVT 
mutated RyR2 bearing R2475S. 
The fact that DPc10 did not directly interact with N-terminal domain was 
surprising, given the finding that DPc10 directly binds to the N-t rminal 
domain 34. This study detected DPc10-labelled fluorescence in a fragment 
of RyR2 (after calpain digestion) which was bound by N-terminal domain 
antibodies. The similar peptide DP4 is also shown to bind the N-terminal 
domain 49, further supporting the notion that these peptides bound 
directly, as opposed to indirectly. Indirect labelling of N-terminal 
fragment could occur if peptides were bound to the HD1 region, which 
was itself bound to the N-terminal domain. Alternatively, it is possible 
there are multiple binding sites, both directly at the N-terminal domain, 
and at the native sequence location. 
As well as the inter-subunit interaction with HD1, the N-terminal domain 
also interacted with the neighbour subunit’s central domain. It has been 
suggested that a region within the central domain, also known as the I 
domain (3722- 4610), is involved in a domain interaction which is crit cal 
in regulating channel gating 32,50. This region, near the N-terminal domain 
interaction with HD1, could well be directly influenced by unzipping of 
these domains.  
The native sequence is embedded within neighbouring helices of the HD1 
region, with most of residue interactions being integral to the region, in a 
stable, undynamic way, which did not move drastically upon channel 
opening. One possibility is that the peptide (and critically the residue Arg 
which gives the peptide functionality) makes an interaction with a few of 
the residues that the native Arg does to interfere and corrupt the normal 
structure. The idea of this Arg being critical is supported by the 
complementary effects of the similar peptide DP4, which shares a similar 
structure, including the Arg residue critical for binding.  
We highlight the discrepancy between the site of the DPc10 sequence 
within HD1 and the reported peptide binding site in the handle (residu s 
1652-2109, aka domain 3 in older nomenclature), near both FKBP and 
CaM 35. The paper does speculate that one DPc10 molecule may bind to 
2 different sites, but the reason for binding at a different site to where the 
native sequence lies is unexplained. We are not ruling out DPc10 binding 
at the native sequence or at the site in the handle, away from the native 
sequence, given the possibility that DPc10 has multiple binding sites on 
the RyR2 35. We suggest that the DPc10 peptide binding interaction is the 
focus of further research. 
 
Materials and Methods 
Peptides  
IpCa peptide was produced as detailed previously 51. IpCa was modified 
with the cyclic imidoester 2-iminothiolane linker to introduce a 
sulfhydryl, which was reacted with fluorescent maleimide Al xa Fluor 
546, as detailed previously 24.
DPc10 peptide sequence is 
(2460)GFCPDHKAAMVLFLDRVYGIEVQDFLLHLLEVGFLP(2495)
. DPc10-FITC and mut-DPc10-FITC (bearing R2474S mutation) were 
synthesised by Peptide Protein Research, the 5’ carboxyfluorescein 
located at the N-terminus of the peptide. The peptides werepurified to 
>95% in acetonitrile and water containing 0.1% trifluoroacetic acid 
(TFA) by HPLC. 
Cardiomyocytes 
All chemicals are sourced from Sigma-Aldrich unless specified 
otherwise. Animal experiments were performed according to UK Home 
Office approved methods. Ventricular cardiomyocytes were isolated 
from adult male Wistar rats using the Langendorff perfusion method as 
described previously 52. Cells were permeabilised in suspension with 10 
µg/ml saponin (from Quillaja bark, S-2149), in a mock intracellular 
solution (concentrations in mM: EGTA, 0.5; KCl, 100; HEPES, 25; 
MgCl, 5.72; ATP, 5; creatine phosphate, 10. pH 7.0 with KOH) for 10 
minutes at room temperature (RT) on a rocker. The free [Ca2+] 
concentration was estimated to be low (50-100 nM) given the additional 
EGTA buffering added to ensure contaminating Ca2+ was removed. 
Following permeabilisation, cells were centrifuged and re-suspended in 
intracellular solution prior to attachment to laminin-coated chambers 
(Thermo Fisher Scientific, 23017015). 11.7 µg/ml laminin coating was 
performed overnight at RT. For IpCa-A546 experiments, permeabilised 
cells were incubated with 30 µM FCCP (C2920) for 10 minutes prior to 
attachment. 
Once attached, permeabilised cells were incubated with 5 µM DPc10-
FITC, mut-DPc10-FITC, IpCa-A546 or FITC (diluted in intracellular 
solution), for 30 minutes unless stated otherwise. Where stat d, 10 mM 
caffeine was including in the peptide incubation step. Cardiomyocytes 
were fixed with 2% paraformaldehyde for 10 minutes at room 
temperature. 
Immunolabelling 
Fixed cells were permeabilised with 0.1% Triton X-100 in PBS for 10 
mins and blocked with 10% normal goat serum (NGS, 10000C, Thermo 
Fisher Scientific) in PBS for one hour, both steps at room temperature. 
Primary antibodies for RyR2 (mouse monoclonal anti-RyR2 IgG1, 
Thermo Fisher Scientific, UK, MA3-916) were diluted to 1:200 in 
incubation solution ((w/v or v/v) 0.05% NaN3; 2% bovine serum albumin 
(Thermo Fisher Scientific); 2% NGS; 0.05% Triton X-100, dissolved in 
PBS) and incubated overnight at 4°C.  
Cells were washed three times in fresh PBS at RT for 20 mins, then 
incubated with goat anti-mouse IgG Alexa Fluor 488 (in the case of IpCa-
A546), or goat anti-mouse IgG Alexa Fluor 594 (in the case of DPc10-
FITC) (A11001, A11005, Thermo Fisher Scientific). 
Imaging and expansion microscopy 
For confocal imaging an inverted LSM700 (Carl Zeiss, Jena) was used 
with a Plan-Aprochromat 40x 1.3 NA objective. Fluorophores were 
excited with 488 nm and 561 nm DPSS lasers, and emission bands were 
selected using the in-built spectral detector.  
proExM was performed as detailed in the cited paper 37. To image 
expanded gels, squares of gel were cut out and placed into acrylic 
chambers onto a glass no. 1.5 coverslip (Menzel Gläser), which ere 
poly-L-lysine coated (0.1%, overnight at RT). 
Software 
Image analysis was performed in Fiji (https://imagej.net/Fiji). 
Colocalisation analysis was implemented using the coloc2 module after 
performing background subtraction. A median filter was applied to 
DPc10-FITC ExM data to remove noise. 
Pymol was used to visualize the peptides and RyR2 cryo-EM structures. 
The following PDB structures were used:  1ie6 (IpCa) 48, 5L1d (rabbit 
RyR2 closed) 44, 5goa 5go9 (porcine RyR2 open and closed) 53, 6ji8 
(porcine RyR2 with FKBP and CaM) 54. 
Jpred4 (http://www.compbio.dundee.ac.uk/jpred4/) was used to predict 
DPc10 peptide secondary structure features. 
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Supplementary Figure 1 – Imperacalcin background. (A) Representative image of the structure of IpCa  demonstrating the 
cluster of positively charged residues (blue) on one side of the molecule forming the dipole moment. (Bi-ii) The exact binding site 
of IpCa on the RyR2 is unconfirmed, but hypothesised to be either at a cytoplasmic moiety far from the pore (annotation in B-i) or 
at a site within the interior of the pore (not shown). 
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Supplementary Figure 2 – Supporting information on DPc10 sequence and peptide binding site. (A) The similar peptide DP4 relates to a similar 
loop/site (red) as DPc10 (yellow), which also involves Arg2475. (B) The DPc10 native sequence region becomes no more accessible in the open 
conformation. (C) The reported DPc10 binding site from FRET experiment (Oda 2013) is a different location to that of the native sequence region. 
DPc10 is reported to be distance 56 Å away from FKBP (orange) ad C M, whereas in the RyR2 structure, DPc10 native sequence is 100 Å from the 
location of the FKBP FRET partner. 
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